BREATH-SENSE: Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbations

患有慢性阻塞性肺疾病（COPD）的患者患有持续性气道阻塞，导致呼吸短促和极度疲劳。患者因急性发作（称为急性加重）而反复住院，这在很大程度上导致了与COPD相关的发病率和死亡率。病情恶化的诊断仅基于症状，而诊断往往为时已晚。目前迫切需要一种可靠的技术，对慢性阻塞性肺病患者进行不显眼的连续在家监测，以便及时预测和治疗病情恶化。breathe - sense联盟的目标是开发有史以来第一个用于无创检测呼吸生物标志物的手持式呼吸分析仪。RespiQ开发了一种突破性的基于等离子体发射光谱的呼吸分析技术，并将与传感器开发专家SINTEF、用户体验和共同创造专家NeLL以及临床COPD专家KCL合作。该联盟将把创新技术进步与以人为中心的用户体验研究相结合，开发和验证一种变革性的COPD患者在家监测临床工作流程。通过这种基于数字生物标志物的监测解决方案，患者和临床医生将受益于可靠和及时的恶化预测，从而进行早期治疗干预，并防止高达95%的住院治疗。breathe - sense工作流程将为COPD管理带来范式转变，从基于症状的延迟诊断转向症状恶化前的预防性家庭监测。最终，呼气测醉器技术是一种平台技术，可以应用于广泛的呼吸系统和胃肠道疾病，也可以在家中更好地持续监测，如哮喘、肺癌和肠易激综合征，因为新的生物标志物可以用于不同的疾病适应症。因此，呼吸感应技术有潜力改善数百万人的健康。

Patients suffering from Chronic Obstructive Pulmonary disease (COPD) suffer from persistent airway obstruction causing shortness of breath and extreme fatigue. Patients are repeatedly hospitalized due to acute flare-ups known as exacerbations, which are largely responsible for the morbidity and mortality associated with COPD. Exacerbations are diagnosed based on symptoms only and diagnosis is often too late. There is an urgent need for a reliable technology for unobtrusive and continuous at-home monitoring of COPD patientsto enable timely exacerbation prediction and treatment. The Breath-Sense consortium aims to develop the first-ever hand-held breathalyzer for non-invasive detection of breath biomarkers. RespiQ has developed a breakthrough plasma emission spectroscopy-based breath analysis technology, and will collaborate with sensor development expert SINTEF, user-experience and co-creation expert NeLL and clinical COPD specialist KCL. The consortium will combine innovative technological advancements with human-centric user-experience research to develop and validate a transformative clinical workflow for at-home monitoring of COPD patients. With this digital biomarker based monitoring solution, patients and clinicians will benefit from reliable and timely prediction of exacerbations, leading to early treatment intervention and preventing up to 95% hospitalizations. The Breath-Sense workflow will deliver a paradigm shift in COPD management, from symptom-based delayed diagnosistowards preventative at-home monitoring prior to symptom worsening. Ultimately, the breathalyzer technology is a platform technology that can be applicable for a wide range of respiratory and gastrointestinal diseases that could also be monitored better continuously at home such as asthma, lung cancer, and IBS,since novel biomarkers can be incorporated for different disease indications. As such, the Breath-Sense technology has the potential to improve the health of millions of people.